Astrocyte differentiation states and glioma formation

Cancer Journal

Volumn 9, Issue 2, 2003, Pages 72-81

  Dai, Chengkai ^a   Holland, Eric C ^a  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

Author keywords

Differentiation inducing therapy; Glial differentiation; Glioma genetics; Gliomagenesis

Indexed keywords

CELL MARKER; GENE PRODUCT; GROWTH FACTOR; PROTEIN TYROSINE KINASE;

ASTROCYTE; ASTROCYTOMA; CELL CYCLE ARREST; CELL DIFFERENTIATION; CELL STRUCTURE; GENE EXPRESSION REGULATION; GENE OVEREXPRESSION; GLIOMA; HUMAN; NEURAL STEM CELL; NONHUMAN; OLIGODENDROGLIOMA; PRIORITY JOURNAL; REVIEW; SIGNAL TRANSDUCTION; TUMOR CELL; TUMOR DIFFERENTIATION; ANIMAL; ANIMAL MODEL; BIOSYNTHESIS; CELL CYCLE; CELL TRANSFORMATION; GLIA; METABOLISM; MOUSE; PATHOLOGY; PHYSIOLOGY;

ANIMALS; ASTROCYTOMA; CELL CYCLE; CELL TRANSFORMATION, NEOPLASTIC; GLIOMA; HUMANS; MICE; MODELS, ANIMAL; NEUROGLIA; RECEPTOR PROTEIN-TYROSINE KINASES; SIGNAL TRANSDUCTION;

EID: 0141835824     PISSN: 15289117     EISSN: 1540336X     Source Type: Journal    
DOI: 10.1097/00130404-200303000-00002     Document Type: Review

References (123)

1. Kleihues P, Louis DN, Scheithauer BW et al. The WHO classification of tumors of the nervous system. J Neuropathol Exp Neurol 2002;61:215-225; discussion 226-229.
2. Louis DN, Holland EC, Cairncross JG. Glioma classification: a molecular reappraisal. Am J Pathol 2001;159:779-786.
3. Le R, Esquenazi S. Astrocytes mediate cerebral cortical neuronal axon and dendrite growth, in part, by release of fibroblast growth factor. Neurol Res 2002;24:81-92.
4. Ye ZC, Sontheimer H. Astrocytes protect neurons from neurotoxic injury by serum glutamate. Glia 1998;22:237-248.
5. Song H, Stevens CF, Gage FH. Astroglia induce neurogenesis from adult neural stem cells. Nature 2002;417:39-44.
6. + oscillations. Brain Res 1994;659:169-178.
7. Hansson E, Ronnback L. Astroglial modulation of synaptic transmission. Perspect Dev Neurobiol 1994;2:217-223.
8. Aschner M. Astrocytes as mediators of immune and inflammatory responses in the CNS. Neurotoxicology 1998;19:269-281.
9. Mucke L, Eddleston M. Astrocytes in infectious and immune-mediated diseases of the central nervous system. FASEB J 1993;7:1226-1232.
10. Armstrong R, Friedrich VL Jr, Holmes KV et al. In vitro analysis of the oligodendrocyte lineage in mice during demyelination and remyelination. J Cell Biol 1990;111:1183-1195.
11. Jacque CM, Vinner C, Kujas M et al. Determination of glial fibrillary acidic protein (GFAP) in human brain tumors. J Neurol Sci 1978;35:147-155.
12. Ingvar M, Schmidt-Kastner R, Meller D. Immunohistochemical markers for neurons and astrocytes show pan-necrosis following infusion of high-dose NMDA into rat cortex. Exp Neurol 1994;128:249-259.
13. Pazanin L, Poljakovic Z, Palic J. Vimentin and glial fibrillary acidic protein expression in relation to neoplastic cell differentiation in glial tumors. Neurol Croat 1992;41:191-203.
14. van Heyningen P, Calver AR, Richardson WD. Control of progenitor cell number by mitogen supply and demand. Curr Biol 2001;11:232-241.
15. Kitchens DL, Snyder EY, Gottlieb DI. FGF and EGF are mitogens for immortalized neural progenitors. J Neurobiol 1994;25:797-807.
16. Burrows RC, Lillien L, Levitt P. Mechanisms of progenitor maturation are conserved in the striatum and cortex. Dev Neurosci 2000;22:7-15.
17. Kornblum HI, Hussain R, Wiesen J et al. Abnormal astrocyte development and neuronal death in mice lacking the epidermal growth factor receptor. J Neurosci Res 1998;53:697-717.
18. Calver AR, Hall AC, Yu WP et al. Oligodendrocyte population dynamics and the role of PDGF in vivo. Neuron 1998;20:869-882.
19. Fruttiger M, Karlsson L, Hall AC et al. Defective oligodendrocyte development and severe hypomyelination in PDGF-A knockout mice. Development 1999;126:457-467.
20. Ye P, Li L, Lund PK, D'Ercole AJ. Deficient expression of insulin receptor substrate-1 (IRS-1) fails to block insulin-like growth factor-I (IGF-I) stimulation of brain growth and myelination. Brain Res Dev Brain Res 2002;136:111-121.
21. Mason JL, Jones JJ, Taniike M et al. Mature oligodendrocyte apoptosis precedes IGF-1 production and oligodendrocyte progenitor accumulation and differentiation during demyelination/remyelination. J Neurosci Res 2000;61:251-262.
22. Ericson J, Muhr J, Placzek M et al. Sonic hedgehog induces the differentiation of ventral forebrain neurons: a common signal for ventral patterning within the neural tube. Cell 1995;81:747-756.
23. Nery S, Wichterle H, Fishell G. Sonic hedgehog contributes to oligodendrocyte specification in the mammalian forebrain. Development 2001;128:527-540.
24. Jarriault S, Le Bail O, Hirsinger E et al. Delta-1 activation of notch-1 signaling results in HES-1 transactivation. Mol Cell Biol 1998;18:7423-7431.
25. Tanigaki K, Nogaki F, Takahashi J et al. Notch1 and Notch3 instructively restrict bFGF-responsive multipotent neural progenitor cells to an astroglial fate. Neuron 2001;29:45-55.
26. Wang S, Sdrulla AD, diSibio G et al. Notch receptor activation inhibits oligodendrocyte differentiation. Neuron 1998;21:63-75.
27. Bonni A, Sun Y, Nadal-Vicens M et al. Regulation of gliogenesis in the central nervous system by the JAK-STAT signaling pathway. Science 1997;278:477-483.
28. Aberg MA, Ryttsen F, Hellgren G et al. Selective introduction of antisense oligonucleotides into single adult CNS progenitor cells using electroporation demonstrates the requirement of STAT3 activation for CNTF-induced gliogenesis. Mol Cell Neurosci 2001;17:426-443.
29. Nakashima K, Takizawa T, Ochiai W et al. BMP2-mediated alteration in the developmental pathway of fetal mouse brain cells from neurogenesis to astrocytogenesis. Proc Natl Acad Sci USA 2001;98:5868-5873.
30. Yanagisawa M, Nakashima K, Takizawa T et al. Signaling crosstalk underlying synergistic induction of astrocyte differentiation by BMPs and IL-6 family of cytokines. FEBS Lett 2001;489:139-143.
31. Zhu G, Mehler MF, Zhao J et al. Sonic hedgehog and BMP2 exert opposing actions on proliferation and differentiation of embryonic neural progenitor cells. Dev Biol 1999;215:118-129.
32. Hu JS, Olson EN. Regulation of differentiation of the BC3H1 muscle cell line through cAMP-dependent and -independent pathways. J Biol Chem 1988;263:19670-19677.
33. McManus MF, Chen LC, Vallejo I et al. Astroglial differentiation of cortical precursor cells triggered by activation of the cAMP-dependent signaling pathway. J Neurosci 1999;19:9004-9015.
34. Degos L, Wang ZY. All trans retinoic acid in acute promyelocytic leukemia. Oncogene 2001;20:7140-7145.
35. Wang Z, Sun G, Shen Z et al. Differentiation therapy for acute promyelocytic leukemia with all-trans retinoic acid: 10-year experience of its clinical application. Chin Med J (Engl) 1999;112:963-967.
36. Wohl CA, Weiss S. Retinoic acid enhances neuronal proliferation and astroglial differentiation in cultures of CNS stem cell-derived precursors. J Neurobiol 1998;37:281-290.
37. Rodriguez-Pena A. Oligodendrocyte development and thyroid hormone. J Neurobiol 1999;40:497-512.
38. Tikoo R, Casaccia-Bonnefil P, Chao MV et al. Changes in cyclin-dependent kinase 2 and p27kip1 accompany glial cell differentiation of central glia-4 cells. J Biol Chem 1997;272:442-447.
39. Zezula J, Casaccia-Bonnefil P, Ezhevsky SA et al. p21cip1 is required for the differentiation of oligodendrocytes independently of cell cycle withdrawal. EMBO Rep 2001;2:27-34.
40. Sah VP, Attardi LD, Mulligan GJ et al. A subset of p53-deficient embryos exhibit exencephaly. Nat Genet 1995;10:175-180.
41. Eizenberg O, Faber-Elman A, Gottlieb E et al. p53 plays a regulatory role in differentiation and apoptosis of central nervous system-associated cells. Mol Cell Biol 1996;16:5178-5185.
42. Kokunai T, Kawamura A, Tamaki N. Induction of differentiation by wild-type p53 gene in a human glioma cell line. J Neurooncol 1997;32:125-133.
43. Kokunai T, Izawa I, Tamaki N. Overexpression of p21WAF1/CIP1 induces cell differentiation and growth inhibition in a human glioma cell line. Int J Cancer 1998;75:643-648.
44. Slack RS, Miller FD. Retinoblastoma gene in mouse neural development. Dev Genet 1996;18:81-91.
45. Galderisi U, Melone MA, Jori FP et al. pRb2/p130 gene overexpression induces astrocyte differentiation. Mol Cell Neurosci 2001;17:415-425.
46. Bachoo RM, Maher EA, Ligon KL et al. Epidermal growth factor receptor and Ink4a/Arf: convergent mechanisms governing terminal differentiation and transformation along the neural stem cell to astrocyte axis. Cancer Cell 2002;1:269-277.
47. Naka K, Yokozaki H, Domen T et al. Growth inhibition of cultured human gastric cancer cells by 9-cis-retinoic acid with induction of cdk inhibitor Waf1/Cip1/Sdi1/p21 protein. Differentiation 1997;61:313-320.
48. Matsuo T, Thiele CJ. p27Kip1: a key mediator of retinoic acid induced growth arrest in the SMS-KCNR human neuroblastoma cell line. Oncogene 1998;16:3337-3343.
49. Grunstein M. Histone acetylation in chromatin structure and transcription. Nature 1997;389:349-352.
50. Kosugi H, Towatari M, Hatano S et al. Histone deacetylase inhibitors are the potent inducer/enhancer of differentiation in acute myeloid leukemia: a new approach to anti-leukemia therapy. Leukemia 1999;13:1316-1324.
51. Richon VM, Sandhoff TW, Rifkind RA et al. Histone deacetylase inhibitor selectively induces p21WAF1 expression and gene-associated histone acetylation. Proc Natl Acad Sci USA 2000;97:10014-10019.
52. Munster PN, Troso-Sandoval T, Rosen N et al. The histone deacetylase inhibitor suberoylanilide hydroxamic acid induces differentiation of human breast cancer cells. Cancer Res 2001;61:8492-8497.
53. Ortega S, Malumbres M, Barbacid M. Cyclin D-dependent kinases, INK4 inhibitors and cancer. Biochim Biophys Acta 2002;1602:73-87.
54. Sherr CJ, Weber JD. The ARF/p53 pathway. Curr Opin Genet Dev 2000;10:94-99.
55. Fleming TP, Saxena A, Clark WC et al. Amplification and/or overexpression of platelet-derived growth factor receptors and epidermal growth factor receptor in human glial tumors. Cancer Res 1992;52:4550-4553.
56. Schlegel J, Merdes A, Stumm G et al. Amplification of the epidermal-growth-factor-receptor gene correlates with different growth behaviour in human glioblastoma. Int J Cancer 1994;56:72-77.
57. Takahashi JA, Mori H, Fukumoto M et al. Gene expression of fibroblast growth factors in human gliomas and meningiomas: demonstration of cellular source of basic fibroblast growth factor mRNA and peptide in tumor tissues. Proc Natl Acad Sci USA 1990;87:5710-5714.
58. Morrison RS, Yamaguchi F, Bruner JM et al. Fibroblast growth factor receptor gene expression and immunoreactivity are elevated in human glioblastoma multiforme. Cancer Res 1994;54:2794-2799.
59. Fleming TP, Saxena A, Clark WC et al. Amplification and/or overexpression of platelet-derived growth factor receptors and epidermal growth factor receptor in human glial tumors. Cancer Res 1992;52:4550-4553.
60. Smith JS, Wang XY, Qian J et al. Amplification of the platelet-derived growth factor receptor-A (PDGFRA) gene occurs in oligodendrogliomas with grade IV anaplastic features. J Neuropathol Exp Neurol 2000;59:495-503.
61. Glick RP, Lichtor T, Unterman TG. Insulin-like growth factors in central nervous system tumors. J Neurooncol 1997;35:315-325.
62. Zumkeller W, Westphal M. The IGF/IGFBP system in CNS malignancy. Mol Pathol 2001;54:227-229.
63. Li J, Yen C, Liaw D et al. PTEN, a putative protein tyrosine phosphatase gene mutated in human brain, breast, and prostate cancer. Science 1997;275:1943-1947.
64. Stambolic V, Suzuki A, de la Pompa JL et al. Negative regulation of PKB/Akt-dependent cell survival by the tumor suppressor PTEN. Cell 1998;95:29-39.
65. Fulci G, Labuhn M, Maier D et al. p53 gene mutation and ink4a-arf deletion appear to be two mutually exclusive events in human glioblastoma. Oncogene 2000;19:3816-3822.
66. Henson JW, Schnitker BL, Correa KM et al. The retinoblastoma gene is involved in malignant progression of astrocytomas. Ann Neurol 1994;36:714-721.
67. Frankel RH, Bayona W, Koslow M et al. p53 mutations in human malignant gliomas: comparison of loss of heterozygosity with mutation frequency. Cancer Res 1992;52:1427-1433.
68. Schmidt EE, Ichimura K, Reifenberger G et al. CDKN2 (p16/MTS1) gene deletion or CDK4 amplification occurs in the majority of glioblastomas. Cancer Res 1994;54:6321-6424.
69. Costello JF, Plass C, Arap W et al. Cyclin-dependent kinase 6 (CDK6) amplification in human gliomas identified using two-dimensional separation of genomic DNA. Cancer Res 1997;57:1250-1254.
70. Buschges R, Weber RG, Actor B et al. Amplification and expression of cyclin D genes (CCND1, CCND2 and CCND3) in human malignant gliomas. Brain Pathol 1999;9:435-442; discussion 432-433.
71. Reifenberger G, Liu L, Ichimura K et al. Amplification and overpression of the MDM2 gene in a subset of human malignant gliomas without p53mutations. Cancer Res 1993;53:2736-2739.
72. Zhou BP, Liao Y, Xia W et al. HER-2/neu induces p53 ubiquitination via Akt-mediated MDM2 phosphorylation. Nat Cell Biol 2001;3:973-982.
73. Dai C, Holland EC. Glioma models. Biochim Biophys Acta 2001;1551:M19-M27.
74. Holland EC. Gliomagenesis: genetic alterations and mouse models. Nat Rev Genet 2001;2:120-129.
75. Guha A, Feldkamp MM, Lau N et al. Proliferation of human malignant astrocytomas is dependent on Ras activation. Oncogene 1997;15:2755-2765.
76. Haas-Kogan D, Shalev N, Wong M et al. Protein kinase B (PKB/ Akt) activity is elevated in glioblastoma cells due to mutation of the tumor suppressor PTEN/MMAC. Curr Biol 1998;8:1195-1198.
77. Greenhalgh DA, Rothnagel JA, Quintanilla MI et al. Induction of epidermal hyperplasia, hyperkeratosis, and papillomas in transgenic mice by a targeted v-Ha-ras oncogene. Mol Carcinog 1993;7:99-110.
78. Wright JT, Hansen L, Mahler J et al. Odontogenic tumours in the v-Ha-ras (TG.AC) transgenic mouse. Arch Oral Biol 1995;40:631-638.
79. Schaffner DL, Barrios R, Shaker MR et al. Transgenic mice carrying a PSArasT24 hybrid gene develop salivary gland and gastrointestinal tract neoplasms. Lab Invest 1995;72:283-290.
80. Ding H, Roncari L, Shannon P et al. Astrocyte-specific expression of activated p21-ras results in malignant astrocytoma formation in a transgenic mouse model of human gliomas. Cancer Res 2001;61:3826-3836.
81. Penuel E, Martin GS. Transformation by v-Src: Ras-MAPK and PI3K-mTOR mediate parallel pathways. Mol Biol Cell 1999;10:1693-1703.
82. Weissenberger J, Steinbach JP, Malin G et al. Development and malignant progression of astrocytomas in GFAP-v-src transgenic mice. Oncogene 1997;14:2005-2013.
83. Uhrbom L, Dai C, Celestino JC et al. Ink4a-Arf loss cooperates with KRas activation in astrocytes and neural progenitors to generate glioblastomas of various morphologies depending on activated Akt. Cancer Res 2002;62:5551-5558.
84. Holland EC, Celestino J, Dai C et al. Combined activation of Ras and Akt in neural progenitors induces glioblastoma formation in mice. Nat Genet 2000;25:55-57.
85. Kahn S, Yamamoto F, Almoguera C et al. The c-K-ras gene and human cancer (review). Anticancer Res 1987;7:639-652.
86. Bos JL. ras oncogenes in human cancer: a review. Cancer Res 1989;49:4682-4689.
87. Marshall CJ. Specificity of receptor tyrosine kinase signaling: transient versus sustained extracellular signal-regulated kinase activation. Cell 1995;80:179-185.
88. Ellis CA, Vos MD, Howell H et al. Rig is a novel Ras-related protein and potential neural tumor suppressor. Proc Natl Acad Sci USA 2002;99:9876-9881.
89. Dunn IF, Heese O, Black PM. Growth factors in glioma angiogenesis: FGFs, PDGF, EGF, and TGFs. J Neurooncol 2000;50:121-137.
90. Morrison RS, Yamaguchi F, Saya H et al. Basic fibroblast growth factor and fibroblast growth factor receptor I are implicated in the growth of human astrocytomas. J Neurooncol 1994;18:207-216.
91. Holland EC, Varmus HE. Basic fibroblast growth factor induces cell migration and proliferation after glia-specific gene transfer in mice. Proc Natl Acad Sci USA 1998;95:1218-1223.
92. Strommer K, Hamou MF, Diggelmann H et al. Cellular and tumoural heterogeneity of EGFR gene amplification in human malignant gliomas. Acta Neurochir 1990;107:82-87.
93. Wong AJ, Ruppert JM, Bigner SH et al. Structural alterations of the epidermal growth factor receptor gene in human gliomas. Proc Natl Acad Sci USA 1992;89:2965-2969.
94. Holland EC, Hively WP, DePinho RA et al. A constitutively active epidermal growth factor receptor cooperates with disruption of G1 cell-cycle arrest pathways to induce glioma-like lesions in mice. Genes Dev 1998;12:3675-3685.
95. Guha A, Dashner K, Black PM et al. Expression of PDGF and PDGF receptors in human astrocytoma operation specimens supports the existence of an autocrine loop. Int J Cancer 1995;60:168-173.
96. Di Rocco F, Carroll RS, Zhang J et al. Platelet-derived growth factor and its receptor expression in human oligodendrogliomas. Neurosurgery 1998;42:341-346.
97. Uhrbom L, Hesselager G, Nister M et al. Induction of brain tumors in mice using a recombinant platelet-derived growth factor B-chain retrovirus. Cancer Res 1998;58:5275-5279.
98. Dai C, Celestino JC, Okada Y et al. PDGF autocrine stimulation dedifferentiates cultured astrocytes and induces oligodendrogliomas and oligoastrocytomas from neural progenitors and astrocytes in vivo. Genes Dev 2001;15:1913-1925.
99. Ivanchuk SM, Mondal S, Dirks PB et al. The INK4A/ARF locus: role in cell cycle control and apoptosis and implications for glioma growth. J Neurooncol 2001;51:219-229.
100. Quelle DE, Zindy F, Ashmun RA et al. Alternative reading frames of the INK4a tumor suppressor gene encode two unrelated proteins capable of inducing cell cycle arrest. Cell 1995;83:993-1000.
101. Sherr CJ. The Pezcoller lecture: cancer cell cycles revisited. Cancer Res 2000;60:3689-3695.
102. Holland EC, Hively WP, Gallo V et al. Modeling mutations in the G1 arrest pathway in human gliomas: overexpression of CDK4 but not loss of INK4a-ARF induces hyperploidy in cultured mouse astrocytes. Genes Dev 1998;12:3644-3649.
103. Serrano M, Lee H, Chin L et al. Role of the INK4a locus in tumor suppression and cell mortality. Cell 1996;85:27-37.
104. Kamijo T, Bodner S, van de Kamp E et al. Tumor spectrum in ARF-deficient mice. Cancer Res 1999;59:2217-2222.
105. Sharpless NE, Bardeesy N, Lee KH et al. Loss of p16Ink4a with retention of p19Arf predisposes mice to tumorigenesis. Nature 2001;413:86-91.
106. Kato H, Kato S, Kumabe T et al. Functional evaluation of p53 and PTEN gene mutations in gliomas. Clin Cancer Res 2000;6:3937-3943.
107. Watanabe T, Yokoo H, Yokoo M et al. Concurrent inactivation of RB1 and TP53 pathways in anaplastic oligodendrogliomas. J Neuropathol Exp Neurol 2001;60:1181-1189.
108. Nozaki M, Tada M, Kobayashi H et al. Roles of the functional loss of p53 and other genes in astrocytoma tumorigenesis and progression. Neurooncol 1999;1:124-137.
109. Donehower LA, Harvey M, Slagle BL et al. Mice deficient for p53 are developmentally normal but susceptible to spontaneous tumours. Nature 1992;356:215-221.
110. Marino S, Vooijs M, van Der Gulden H et al. Induction of medulloblastomas in p53-null mutant mice by somatic inactivation of Rb in the external granular layer cells of the cerebellum. Genes Dev 2000;14:994-1004.
111. Xiao A, Wu H, Pandolfi PP, Louis DN et al. Astrocyte inactivation of the pRb pathway predisposes mice to malignant astrocytoma development that is accelerated by PTEN mutation. Cancer Cell 2002;1:157-168.
112. Huang ZY, Baldwin RL, Hedrick NM et al. Astrocyte-specific expression of CDK4 is not sufficient for tumor formation, but cooperates with p53 heterozygosity to provide a growth advantage for astrocytes in vivo. Oncogene 2002;21:1325-1334.
113. Bajenaru ML, Zhu Y, Hedrick NM et al. Astrocyte-specific inactivation of the neurofibromatosis 1 gene (NF1) is insufficient for astrocytoma formation. Mol Cell Biol 2002;22:5100-5113.
114. Reilly KM, Loisel DA, Bronson RT et al. Nf1;Trp53 mutant mice develop glioblastoma with evidence of strain-specific effects. Nat Genet 2000;26:109-113.
115. Ballester R, Marchuk D, Boguski M et al. The NF1 locus encodes a protein functionally related to mammalian GAP and yeast IRA proteins. Cell 1990;63:851-859.
116. Bollag G, Clapp DW, Shih S et al. Loss of NF1 results in activation of the Ras signaling pathway and leads to aberrant growth in haematopoietic cells. Nat Genet 1996;12:144-148.
117. Haydon RC, Zhou L, Feng T et al. Nuclear receptor agonists as potential differentiation therapy agents for human osteosarcoma. Clin Cancer Res 2002;8:1288-1294.
118. Munster PN, Troso-Sandoval T, Rosen N et al. The histone deacetylase inhibitor suberoylanilide hydroxamic acid induces differentiation of human breast cancer cells. Cancer Res 2001;61:8492-8497.
119. Chang TH, Szabo E. Enhanced growth inhibition by combination differentiation therapy with ligands of peroxisome proliferator-activated receptor-gamma and inhibitors of histone deacetylase in adenocarcinoma of the lung. Clin Cancer Res 2002;8:1206-1212.
120. Riecken EO, Rosewicz S. Retinoids in pancreatic cancer. Ann Oncol 1999;10[suppl 4]:197-200.
121. Engelhard HH, Duncan HA, Kim S et al. Therapeutic effects of sodium butyrate on glioma cells in vitro and in the rat C6 glioma model. Neurosurgery 2001;48:616-624; discussion 624-625.
122. Jendrossek V, Kugler W, Erdlenbruch B et al. Induction of differentiation and tetraploidy by long-term treatment of C6 rat glioma cells with erucylphosphocholine. Int J Oncol 2001;19:673-680.
123. Costa SL, Paillaud E, Fages C et al. Effects of a novel synthetic retinoid on malignant glioma in vitro: inhibition of cell proliferation, induction of apoptosis and differentiation. Eur J Cancer 2001;37:520-530.